Why are PPAR agonists a promising option for the management of NASH ?

Prof. Sven Francque, Chair of the PanNASH initiative reviews the current management options in NASH and the many molecules in development. It sheds light on the rationale for PPAR agonists as a promising and very valuable therapeutic option with systemic potential, for what happens in the liver and outside of the liver.
Play Video

Prof. Sven Francque, Chair of the PanNASH initiative reviews the current management options in NASH and the many molecules in development. It sheds light on the rationale for PPAR agonists as  a promising and very valuable therapeutic  option with systemic potential, for what happens in the liver and outside of the liver.

Prof. Sven Francque

Prof. Sven Francque

Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.

SUBSCRIBE & FOLLOW US

Subscribe Our Newsletter To Get the Lastest Updates